Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma

Background Apoptosis is one of the major events following total androgen blockade (TAB). The aim of this study was to determine the predictive value of some histological parameters including apoptosis and gene products which influence apoptosis, based on repeated biopsies taken from the same patient...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Prostate 2001-10, Vol.49 (2), p.93-100
Hauptverfasser: Szende, B., Romics, I., Minik, K., Szabó, J., Torda, I., Lovász, S., Szomor, L., Tóth, L., Bély, M., Kerényi, T., Bartók, K., Végh, A.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 100
container_issue 2
container_start_page 93
container_title The Prostate
container_volume 49
creator Szende, B.
Romics, I.
Minik, K.
Szabó, J.
Torda, I.
Lovász, S.
Szomor, L.
Tóth, L.
Bély, M.
Kerényi, T.
Bartók, K.
Végh, A.
description Background Apoptosis is one of the major events following total androgen blockade (TAB). The aim of this study was to determine the predictive value of some histological parameters including apoptosis and gene products which influence apoptosis, based on repeated biopsies taken from the same patients. Methods At the time of diagnosis by needle biopsy TNM stage, serum PSA, Gleason's grade, apoptotic and mitotic index, Ki67, p53, and bcl2 expression were investigated in 60 prostate carcinoma patients. Antiandrogen therapy supplemented with surgical or chemical castration was administered. Serum PSA‐test and needle biopsy were repeated 13–14 weeks after starting the therapy, simultaneously with determination of the apoptotic and mitotic index, Ki67, p53, and bcl2 expression. Results Forty‐seven patients were alive at the end of the study, 13 patients died. Decrease in mitotic, increase in apoptotic index predicted favourable long‐term response to antiandrogen therapy. Lower Ki67 and (mutant) p53 expression in the first and also in the second biopsy pointed to favourable effect of antiandrogen treatment. Since the ratio between Ki67 and apoptotic index strongly decreased in the survivors upon therapy, changes in Ki67/apoptosis ratio is recommended as a histologically detectable predictive factor. bcl2 expression did not show significant correlation with the outcome of the disease. Conclusions Histological evaluation of mitotic and apoptotic index, Ki67, and p53 expression in repeated biopsies contributes to predicting the value of the actual treatment and may be useful to institute alterations in therapy. Prostate 49:93–100, 2001. © 2001 Wiley‐Liss, Inc.
doi_str_mv 10.1002/pros.1122
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71216720</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71216720</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4182-20840b6704804316d3e97789e1d9bb7bc5e2ca6b7b666018b1efcd94d6ae7e7d3</originalsourceid><addsrcrecordid>eNp10E1P2zAYB3BrAq2F7bAvgHJhEofQx45jO0dUrYWpgq3bhLSL5ThPhCFNQpzw8u1x14iedrIPv-ftT8gXCucUgM3arvHnlDL2gUwpZDIG4OkBmQKTEHOayAk58v4eIGhgH8mE0lSxVMkpWa2xRdNjEeWuab1DH7k6widTDaZ3TR01ZdTfYWdaHHpnIyxLtP0_tJ3ah9LIms66utmYT-SwNJXHz-N7TP4svv2eX8arm-XV_GIVW04VixkoDrmQwBXwhIoiwUxKlSEtsjyXuU2RWSPCTwgBVOUUS1tkvBAGJcoiOSZfd33DCo8D-l5vnLdYVabGZvBaUkaFZBDg2Q7asKvvsNRt5zame9UU9DY6vT1Cb6ML9mRsOuQbLPZyzCqA0xEYb01Vdqa2zu8dB8kUV8HNdu7ZVfj6_4n6x_rm1zg63lU43-PLe4XpHrSQiUz17fVS36bp35-L9LueJ2_VG5Uw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71216720</pqid></control><display><type>article</type><title>Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Szende, B. ; Romics, I. ; Minik, K. ; Szabó, J. ; Torda, I. ; Lovász, S. ; Szomor, L. ; Tóth, L. ; Bély, M. ; Kerényi, T. ; Bartók, K. ; Végh, A.</creator><creatorcontrib>Szende, B. ; Romics, I. ; Minik, K. ; Szabó, J. ; Torda, I. ; Lovász, S. ; Szomor, L. ; Tóth, L. ; Bély, M. ; Kerényi, T. ; Bartók, K. ; Végh, A.</creatorcontrib><description>Background Apoptosis is one of the major events following total androgen blockade (TAB). The aim of this study was to determine the predictive value of some histological parameters including apoptosis and gene products which influence apoptosis, based on repeated biopsies taken from the same patients. Methods At the time of diagnosis by needle biopsy TNM stage, serum PSA, Gleason's grade, apoptotic and mitotic index, Ki67, p53, and bcl2 expression were investigated in 60 prostate carcinoma patients. Antiandrogen therapy supplemented with surgical or chemical castration was administered. Serum PSA‐test and needle biopsy were repeated 13–14 weeks after starting the therapy, simultaneously with determination of the apoptotic and mitotic index, Ki67, p53, and bcl2 expression. Results Forty‐seven patients were alive at the end of the study, 13 patients died. Decrease in mitotic, increase in apoptotic index predicted favourable long‐term response to antiandrogen therapy. Lower Ki67 and (mutant) p53 expression in the first and also in the second biopsy pointed to favourable effect of antiandrogen treatment. Since the ratio between Ki67 and apoptotic index strongly decreased in the survivors upon therapy, changes in Ki67/apoptosis ratio is recommended as a histologically detectable predictive factor. bcl2 expression did not show significant correlation with the outcome of the disease. Conclusions Histological evaluation of mitotic and apoptotic index, Ki67, and p53 expression in repeated biopsies contributes to predicting the value of the actual treatment and may be useful to institute alterations in therapy. Prostate 49:93–100, 2001. © 2001 Wiley‐Liss, Inc.</description><identifier>ISSN: 0270-4137</identifier><identifier>EISSN: 1097-0045</identifier><identifier>DOI: 10.1002/pros.1122</identifier><identifier>PMID: 11582587</identifier><identifier>CODEN: PRSTDS</identifier><language>eng</language><publisher>New York: John Wiley &amp; Sons, Inc</publisher><subject>Age Factors ; Aged ; Androgen Antagonists - therapeutic use ; Antineoplastic Agents, Hormonal - therapeutic use ; Apoptosis - drug effects ; apoptotic and mitotic index ; bcl2 ; Biological and medical sciences ; Biopsy ; Carcinoma - drug therapy ; Carcinoma - pathology ; Humans ; Immunohistochemistry ; Ki-67 Antigen - biosynthesis ; Ki67 ; Male ; Medical sciences ; Mitotic Index ; Neoplasm Staging ; Nephrology. Urinary tract diseases ; p53 ; prostate carcinoma ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - drug therapy ; Prostatic Neoplasms - pathology ; Proto-Oncogene Proteins c-bcl-2 - biosynthesis ; Tumor Suppressor Protein p53 - biosynthesis ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>The Prostate, 2001-10, Vol.49 (2), p.93-100</ispartof><rights>Copyright © 2001 Wiley‐Liss, Inc.</rights><rights>2002 INIST-CNRS</rights><rights>Copyright 2001 Wiley-Liss, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4182-20840b6704804316d3e97789e1d9bb7bc5e2ca6b7b666018b1efcd94d6ae7e7d3</citedby><cites>FETCH-LOGICAL-c4182-20840b6704804316d3e97789e1d9bb7bc5e2ca6b7b666018b1efcd94d6ae7e7d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpros.1122$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpros.1122$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=14072848$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11582587$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Szende, B.</creatorcontrib><creatorcontrib>Romics, I.</creatorcontrib><creatorcontrib>Minik, K.</creatorcontrib><creatorcontrib>Szabó, J.</creatorcontrib><creatorcontrib>Torda, I.</creatorcontrib><creatorcontrib>Lovász, S.</creatorcontrib><creatorcontrib>Szomor, L.</creatorcontrib><creatorcontrib>Tóth, L.</creatorcontrib><creatorcontrib>Bély, M.</creatorcontrib><creatorcontrib>Kerényi, T.</creatorcontrib><creatorcontrib>Bartók, K.</creatorcontrib><creatorcontrib>Végh, A.</creatorcontrib><title>Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma</title><title>The Prostate</title><addtitle>Prostate</addtitle><description>Background Apoptosis is one of the major events following total androgen blockade (TAB). The aim of this study was to determine the predictive value of some histological parameters including apoptosis and gene products which influence apoptosis, based on repeated biopsies taken from the same patients. Methods At the time of diagnosis by needle biopsy TNM stage, serum PSA, Gleason's grade, apoptotic and mitotic index, Ki67, p53, and bcl2 expression were investigated in 60 prostate carcinoma patients. Antiandrogen therapy supplemented with surgical or chemical castration was administered. Serum PSA‐test and needle biopsy were repeated 13–14 weeks after starting the therapy, simultaneously with determination of the apoptotic and mitotic index, Ki67, p53, and bcl2 expression. Results Forty‐seven patients were alive at the end of the study, 13 patients died. Decrease in mitotic, increase in apoptotic index predicted favourable long‐term response to antiandrogen therapy. Lower Ki67 and (mutant) p53 expression in the first and also in the second biopsy pointed to favourable effect of antiandrogen treatment. Since the ratio between Ki67 and apoptotic index strongly decreased in the survivors upon therapy, changes in Ki67/apoptosis ratio is recommended as a histologically detectable predictive factor. bcl2 expression did not show significant correlation with the outcome of the disease. Conclusions Histological evaluation of mitotic and apoptotic index, Ki67, and p53 expression in repeated biopsies contributes to predicting the value of the actual treatment and may be useful to institute alterations in therapy. Prostate 49:93–100, 2001. © 2001 Wiley‐Liss, Inc.</description><subject>Age Factors</subject><subject>Aged</subject><subject>Androgen Antagonists - therapeutic use</subject><subject>Antineoplastic Agents, Hormonal - therapeutic use</subject><subject>Apoptosis - drug effects</subject><subject>apoptotic and mitotic index</subject><subject>bcl2</subject><subject>Biological and medical sciences</subject><subject>Biopsy</subject><subject>Carcinoma - drug therapy</subject><subject>Carcinoma - pathology</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Ki-67 Antigen - biosynthesis</subject><subject>Ki67</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mitotic Index</subject><subject>Neoplasm Staging</subject><subject>Nephrology. Urinary tract diseases</subject><subject>p53</subject><subject>prostate carcinoma</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Proto-Oncogene Proteins c-bcl-2 - biosynthesis</subject><subject>Tumor Suppressor Protein p53 - biosynthesis</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0270-4137</issn><issn>1097-0045</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10E1P2zAYB3BrAq2F7bAvgHJhEofQx45jO0dUrYWpgq3bhLSL5ThPhCFNQpzw8u1x14iedrIPv-ftT8gXCucUgM3arvHnlDL2gUwpZDIG4OkBmQKTEHOayAk58v4eIGhgH8mE0lSxVMkpWa2xRdNjEeWuab1DH7k6widTDaZ3TR01ZdTfYWdaHHpnIyxLtP0_tJ3ah9LIms66utmYT-SwNJXHz-N7TP4svv2eX8arm-XV_GIVW04VixkoDrmQwBXwhIoiwUxKlSEtsjyXuU2RWSPCTwgBVOUUS1tkvBAGJcoiOSZfd33DCo8D-l5vnLdYVabGZvBaUkaFZBDg2Q7asKvvsNRt5zame9UU9DY6vT1Cb6ML9mRsOuQbLPZyzCqA0xEYb01Vdqa2zu8dB8kUV8HNdu7ZVfj6_4n6x_rm1zg63lU43-PLe4XpHrSQiUz17fVS36bp35-L9LueJ2_VG5Uw</recordid><startdate>20011001</startdate><enddate>20011001</enddate><creator>Szende, B.</creator><creator>Romics, I.</creator><creator>Minik, K.</creator><creator>Szabó, J.</creator><creator>Torda, I.</creator><creator>Lovász, S.</creator><creator>Szomor, L.</creator><creator>Tóth, L.</creator><creator>Bély, M.</creator><creator>Kerényi, T.</creator><creator>Bartók, K.</creator><creator>Végh, A.</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley-Liss</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20011001</creationdate><title>Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma</title><author>Szende, B. ; Romics, I. ; Minik, K. ; Szabó, J. ; Torda, I. ; Lovász, S. ; Szomor, L. ; Tóth, L. ; Bély, M. ; Kerényi, T. ; Bartók, K. ; Végh, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4182-20840b6704804316d3e97789e1d9bb7bc5e2ca6b7b666018b1efcd94d6ae7e7d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Age Factors</topic><topic>Aged</topic><topic>Androgen Antagonists - therapeutic use</topic><topic>Antineoplastic Agents, Hormonal - therapeutic use</topic><topic>Apoptosis - drug effects</topic><topic>apoptotic and mitotic index</topic><topic>bcl2</topic><topic>Biological and medical sciences</topic><topic>Biopsy</topic><topic>Carcinoma - drug therapy</topic><topic>Carcinoma - pathology</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Ki-67 Antigen - biosynthesis</topic><topic>Ki67</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mitotic Index</topic><topic>Neoplasm Staging</topic><topic>Nephrology. Urinary tract diseases</topic><topic>p53</topic><topic>prostate carcinoma</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Proto-Oncogene Proteins c-bcl-2 - biosynthesis</topic><topic>Tumor Suppressor Protein p53 - biosynthesis</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Szende, B.</creatorcontrib><creatorcontrib>Romics, I.</creatorcontrib><creatorcontrib>Minik, K.</creatorcontrib><creatorcontrib>Szabó, J.</creatorcontrib><creatorcontrib>Torda, I.</creatorcontrib><creatorcontrib>Lovász, S.</creatorcontrib><creatorcontrib>Szomor, L.</creatorcontrib><creatorcontrib>Tóth, L.</creatorcontrib><creatorcontrib>Bély, M.</creatorcontrib><creatorcontrib>Kerényi, T.</creatorcontrib><creatorcontrib>Bartók, K.</creatorcontrib><creatorcontrib>Végh, A.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>The Prostate</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Szende, B.</au><au>Romics, I.</au><au>Minik, K.</au><au>Szabó, J.</au><au>Torda, I.</au><au>Lovász, S.</au><au>Szomor, L.</au><au>Tóth, L.</au><au>Bély, M.</au><au>Kerényi, T.</au><au>Bartók, K.</au><au>Végh, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma</atitle><jtitle>The Prostate</jtitle><addtitle>Prostate</addtitle><date>2001-10-01</date><risdate>2001</risdate><volume>49</volume><issue>2</issue><spage>93</spage><epage>100</epage><pages>93-100</pages><issn>0270-4137</issn><eissn>1097-0045</eissn><coden>PRSTDS</coden><abstract>Background Apoptosis is one of the major events following total androgen blockade (TAB). The aim of this study was to determine the predictive value of some histological parameters including apoptosis and gene products which influence apoptosis, based on repeated biopsies taken from the same patients. Methods At the time of diagnosis by needle biopsy TNM stage, serum PSA, Gleason's grade, apoptotic and mitotic index, Ki67, p53, and bcl2 expression were investigated in 60 prostate carcinoma patients. Antiandrogen therapy supplemented with surgical or chemical castration was administered. Serum PSA‐test and needle biopsy were repeated 13–14 weeks after starting the therapy, simultaneously with determination of the apoptotic and mitotic index, Ki67, p53, and bcl2 expression. Results Forty‐seven patients were alive at the end of the study, 13 patients died. Decrease in mitotic, increase in apoptotic index predicted favourable long‐term response to antiandrogen therapy. Lower Ki67 and (mutant) p53 expression in the first and also in the second biopsy pointed to favourable effect of antiandrogen treatment. Since the ratio between Ki67 and apoptotic index strongly decreased in the survivors upon therapy, changes in Ki67/apoptosis ratio is recommended as a histologically detectable predictive factor. bcl2 expression did not show significant correlation with the outcome of the disease. Conclusions Histological evaluation of mitotic and apoptotic index, Ki67, and p53 expression in repeated biopsies contributes to predicting the value of the actual treatment and may be useful to institute alterations in therapy. Prostate 49:93–100, 2001. © 2001 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>John Wiley &amp; Sons, Inc</pub><pmid>11582587</pmid><doi>10.1002/pros.1122</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0270-4137
ispartof The Prostate, 2001-10, Vol.49 (2), p.93-100
issn 0270-4137
1097-0045
language eng
recordid cdi_proquest_miscellaneous_71216720
source MEDLINE; Wiley Online Library Journals Frontfile Complete
subjects Age Factors
Aged
Androgen Antagonists - therapeutic use
Antineoplastic Agents, Hormonal - therapeutic use
Apoptosis - drug effects
apoptotic and mitotic index
bcl2
Biological and medical sciences
Biopsy
Carcinoma - drug therapy
Carcinoma - pathology
Humans
Immunohistochemistry
Ki-67 Antigen - biosynthesis
Ki67
Male
Medical sciences
Mitotic Index
Neoplasm Staging
Nephrology. Urinary tract diseases
p53
prostate carcinoma
Prostate-Specific Antigen - blood
Prostatic Neoplasms - drug therapy
Prostatic Neoplasms - pathology
Proto-Oncogene Proteins c-bcl-2 - biosynthesis
Tumor Suppressor Protein p53 - biosynthesis
Tumors of the urinary system
Urinary tract. Prostate gland
title Repeated biopsies in evaluation of therapeutic effects in prostate carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T05%3A24%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Repeated%20biopsies%20in%20evaluation%20of%20therapeutic%20effects%20in%20prostate%20carcinoma&rft.jtitle=The%20Prostate&rft.au=Szende,%20B.&rft.date=2001-10-01&rft.volume=49&rft.issue=2&rft.spage=93&rft.epage=100&rft.pages=93-100&rft.issn=0270-4137&rft.eissn=1097-0045&rft.coden=PRSTDS&rft_id=info:doi/10.1002/pros.1122&rft_dat=%3Cproquest_cross%3E71216720%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71216720&rft_id=info:pmid/11582587&rfr_iscdi=true